Targeting Ras-Driven Cancer Cell Survival and Invasion through Selective Inhibition of DOCK1
Hirotada Tajiri,
Takehito Uruno,
Takahiro Shirai,
Daisuke Takaya,
Shigeki Matsunaga,
Daiki Setoyama,
Mayuki Watanabe,
Mutsuko Kukimoto-Niino,
Kounosuke Oisaki,
Miho Ushijima,
Fumiyuki Sanematsu,
Teruki Honma,
Takaho Terada,
Eiji Oki,
Senji Shirasawa,
Yoshihiko Maehara,
Dongchon Kang,
Jean-François Côté,
Shigeyuki Yokoyama,
Motomu Kanai,
Yoshinori Fukui
Affiliations
Hirotada Tajiri
Division of Immunogenetics, Department of Immunobiology and Neuroscience, Medical Institute of Bioregulation, Kyushu University, Fukuoka 812-8582, Japan; Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan
Takehito Uruno
Division of Immunogenetics, Department of Immunobiology and Neuroscience, Medical Institute of Bioregulation, Kyushu University, Fukuoka 812-8582, Japan; Research Center for Advanced Immunology, Kyushu University, Fukuoka 812-8582, Japan
Takahiro Shirai
Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo 113-0033, Japan
Daisuke Takaya
RIKEN Center for Life Science Technologies, Yokohama 230-0045, Japan
Shigeki Matsunaga
Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan
Daiki Setoyama
Department of Clinical Chemistry and Laboratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan
Mayuki Watanabe
Division of Immunogenetics, Department of Immunobiology and Neuroscience, Medical Institute of Bioregulation, Kyushu University, Fukuoka 812-8582, Japan; Research Center for Advanced Immunology, Kyushu University, Fukuoka 812-8582, Japan
Mutsuko Kukimoto-Niino
RIKEN Center for Life Science Technologies, Yokohama 230-0045, Japan
Kounosuke Oisaki
Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo 113-0033, Japan
Miho Ushijima
Division of Immunogenetics, Department of Immunobiology and Neuroscience, Medical Institute of Bioregulation, Kyushu University, Fukuoka 812-8582, Japan
Fumiyuki Sanematsu
Division of Immunogenetics, Department of Immunobiology and Neuroscience, Medical Institute of Bioregulation, Kyushu University, Fukuoka 812-8582, Japan; Research Center for Advanced Immunology, Kyushu University, Fukuoka 812-8582, Japan
Teruki Honma
RIKEN Center for Life Science Technologies, Yokohama 230-0045, Japan
Takaho Terada
RIKEN Structural Biology Laboratory, Yokohama 230-0045, Japan
Eiji Oki
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan
Senji Shirasawa
Department of Cell Biology, Faculty of Medicine, Fukuoka University, Fukuoka 814-0180, Japan
Yoshihiko Maehara
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan
Dongchon Kang
Department of Clinical Chemistry and Laboratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan
Jean-François Côté
Institut de Recherches Cliniques de Montréal (Université de Montréal), Montréal, QC H2W 1R7, Canada
Shigeyuki Yokoyama
RIKEN Structural Biology Laboratory, Yokohama 230-0045, Japan
Motomu Kanai
Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo 113-0033, Japan
Yoshinori Fukui
Division of Immunogenetics, Department of Immunobiology and Neuroscience, Medical Institute of Bioregulation, Kyushu University, Fukuoka 812-8582, Japan; Research Center for Advanced Immunology, Kyushu University, Fukuoka 812-8582, Japan; Corresponding author
Summary: Oncogenic Ras plays a key role in cancer initiation but also contributes to malignant phenotypes by stimulating nutrient uptake and promoting invasive migration. Because these latter cellular responses require Rac-mediated remodeling of the actin cytoskeleton, we hypothesized that molecules involved in Rac activation may be valuable targets for cancer therapy. We report that genetic inactivation of the Rac-specific guanine nucleotide exchange factor DOCK1 ablates both macropinocytosis-dependent nutrient uptake and cellular invasion in Ras-transformed cells. By screening chemical libraries, we have identified 1-(2-(3′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)-2-oxoethyl)-5-pyrrolidinylsulfonyl-2(1H)-pyridone (TBOPP) as a selective inhibitor of DOCK1. TBOPP dampened DOCK1-mediated invasion, macropinocytosis, and survival under the condition of glutamine deprivation without impairing the biological functions of the closely related DOCK2 and DOCK5 proteins. Furthermore, TBOPP treatment suppressed cancer metastasis and growth in vivo in mice. Our results demonstrate that selective pharmacological inhibition of DOCK1 could be a therapeutic approach to target cancer cell survival and invasion. : Tajiri et al. find that the Rac-specific guanine nucleotide exchange factor DOCK1 is required for oncogenic Ras-driven nutrient uptake and cellular invasion. Through chemical library screening, they identify TBOPP as a DOCK1-selective inhibitor that suppresses growth and metastasis of Ras-transformed cancer cells in vivo. Keywords: Ras, cancer cell survival, cancer cell invasion, metabolism, macropinocytosis, DOCK1, small-molecule inhibitor